COVID-19

Pharmacists can review clinical evidence and CDC recommendations before providing information.

But will policy and program administrators make optimal use of existing primary care and pharmacy systems?

These special immune system defense molecules help show which individuals are most at risk of needing intensive care and need to be monitored more closely, new study results show.

Results of a new study show that the vaccines seldomly reach the area that were heavily affected by the pandemic, because of ethnic, racial, and socioeconomic disparities.

The results of a new study show that when coronavirus-infected diabetic mice were injected with an interferon beta, SETDB2 increased and helped decrease the inflammatory cytokines.

Six-point plan outlines strategies to increase national vaccination rates, keep schools open, increase testing and masking access, and to relieve health systems that are overrun with COVID-19 patients.

The results of a new study show that exposure to the viruses produces a protective ‘universal coronavirus’ memory.

The investigators said that even patients with asthma showed no statistically significant deterioration in lung function, although there was a trend toward slightly lower measurements for the amount of air they could exhale forcibly in 1 second.

Guarding against external air pollution while reducing the risk of infection when driving presents a challenge.

Michael Ganio, PharmD, MS, BCPS, FASHP, Senior Director of Pharmacy Practice and Quality at the American Society of Health-System Pharmacists, discussed the recent strains for hospitals due to the newest wave of COVID-19.

Convalescent plasma, IVIG, and remdesivir have successfully helped immunocompromised patients recover from the virus.

The guidance noted it is preferable for immunocompromised patients to receive their third dose in a health care delivery setting rather than a pharmacy or public vaccination clinic.

COVID-19 convalescent plasma administered within the first week of symptoms did not prevent disease progression in a high-risk group of outpatients.

Study indicates that patients with asthma should continue taking their asthma medications during the COVID-19 pandemic.

Following a phase 2 study, Moderna submitted initial data to the FDA for the approval of its COVID-19 booster shot that would be administered 6 months after an individual’s second dose.

Calls to poison control centers regarding the use of ivermectin for the prevention or treatment of COVID-19 have increased 5-fold since its baseline before the COVID-19 pandemic.

The study authors note that they cannot conclude that there is a causal relationship between the COVID-19 vaccines and any of the individual incidents of Bell palsy reviewed.

AZD7442 reduced the risk of developing symptomatic COVID-19 by 77% compared to placebo.

Individuals with COVID-19 were more likely to be asymptomatic if they contracted the virus from a primary case that was also asymptomatic.

Christie Boutte, PharmD, RPh, also discussed how the FDA approval gives pharmacists more tools to encourage patients who may be hesitant about vaccination.

Further, their status was evaluated at 14, 21, and 28 days after treatment, and at each point, the numbers of hospitalization were significantly lower in the treated group.

The investigators, from Washington University School of Medicine in St. Louis, note that the responses measured were one-third as strong as those mounted by healthy individuals.

The Pharmacy Times® Pharmacy Focus podcast provides the latest industry news and information, thought-leader insights, clinical updates, patient counseling tools, and innovative solutions for the everyday practice and business of pharmacy.

Pharmacy Times spoke with Ilisa Bernstein, APhA senior vice president, Pharmacy Practice and Government Affairs, about the latest FDA approval of the Pfizer-BioNTech COVID-19 vaccine.